Sutimlimab Cad denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sutimlimab for Cold Agglutinin Disease — Prior Authorization Required

Prior authorization (PA) is routinely required by BCBS for high-cost specialty biologics, including sutimlimab for cold agglutinin disease (CAD). A PA denial means either that authorization was not obtained before the prescription was dispensed, or that the authorization request was submitted but did not satisfy BCBS's clinical criteria. These two situations call for different strategies: a retroactive authorization appeal versus a prospective medical necessity appeal. Identifying which situation applies is the first step.

## Why This Denial Is Appealable

For CAD — a rare disease with few treatment alternatives — the prior authorization criteria BCBS applies must be grounded in the FDA-approved prescribing information and applicable hematology guidelines. If the patient's clinical profile satisfies those criteria and the documentation submitted was complete and accurate, the denial is reversible. If authorization was not sought in advance because of a prescriber office error or urgent clinical need, retroactive authorization may be available under the plan terms. In either case, a well-documented appeal that directly addresses each PA criterion has a high likelihood of success.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the plan's deadline from the denial date. Request in writing the complete prior authorization criteria BCBS applied and identify the specific criterion the submission did not satisfy.
• Peer-to-peer review: Request a peer-to-peer call between the treating hematologist and the BCBS medical director. For rare hematologic conditions, this conversation often resolves PA denials faster than a written appeal.
• External review (ACA §2719): After a final adverse internal decision, request independent external review within approximately four months. An IRO with hematology expertise will evaluate whether the PA denial was clinically appropriate.
• ERISA §503: Self-funded plan members may request the full administrative record and the specific PA criteria.
• Expedited review: Request if the patient faces clinical urgency — for example, transfusion dependence, progressive hemolysis, or hospitalization risk. Decisions are required within 72 hours.

## Documentation to Gather

• Confirmed CAD diagnosis: relevant laboratory results (cold agglutinin titer, DAT, hemolytic markers) and clinical history
• Disease severity documentation: transfusion history (dates and number of units), symptom burden, quality-of-life impact as recorded in the chart
• Prior treatment history: all prior agents or management strategies, with dates, duration, and documented response or failure
• Treating hematologist's medical necessity letter specifically addressing BCBS's PA criteria
• FDA prescribing information for sutimlimab identifying the approved indication
• BCBS's published prior authorization criteria for sutimlimab (available from the provider line or BCBS's coverage policy portal)
• Any prior authorization submission records and communications

## Criteria-Mapping Structure

Request the exact PA criteria from BCBS in writing or from their published coverage policy. For each criterion, create a direct mapping to the specific chart documentation that satisfies it. If a criterion requires documentation of prior treatment failure, provide dates, agents, and recorded outcomes. If a criterion references the FDA-approved label, cite the label directly. Present this as a structured checklist in the appeal letter so the reviewer can verify compliance criterion by criterion, rather than requiring them to search for evidence across a narrative submission.